G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer?
Authors:
Open Access
- 17 February 2015
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 6, 24
Abstract
G-protein coupled receptors (GPCRs) constitute the largest family of membrane receptors, with high potential for drug discovery. These receptors can be activated by a panel of different ligands including ions, hormones, small molecules and vasoactive peptides. Among those, angiotensins (angiotensin II and angiotensin 1-7) are the major biologically active products of the classical and alternative Renin-Angiotensin System (RAS). These peptides bind and activate three different subtypes of GPCRs, namely AT1, AT2 and Mas receptors, to regulate cardiovascular functions. Over the past decade, the contribution of several RAS components in tumorigenesis has emerged as a novel important concept, Angiotensin II being considered as harmful and Angiotensin 1-7 as protective against cancer. Development of selective ligands targeting each RAS receptor may provide novel and efficient targeted therapeutic strategies against cancer. In this review, we focus on breast cancer to summarize current knowledge on angiotensin receptors (AT1, AT2, and Mas), and discuss the potential use of angiotensin receptor agonists and antagonists in clinics.Keywords
This publication has 79 references indexed in Scilit:
- Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic responseClinical and Translational Oncology, 2013
- Recent advances involving the renin–angiotensin systemExperimental Cell Research, 2012
- A Novel Cellular Model to Study Angiotensin II AT2 Receptor Function in Breast Cancer CellsInternational Journal of Peptides, 2011
- Down‐regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinomaMolecular Oncology, 2011
- Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumorsProceedings of the National Academy of Sciences, 2011
- AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistProceedings of the National Academy of Sciences, 2009
- Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factorMolecular Cancer Therapeutics, 2009
- Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosisBritish Journal of Cancer, 2008
- Genomic assessments of the frequent loss of heterozygosity region on 8p21.3∼p22 in head and neck squamous cell carcinomaCancer Genetics and Cytogenetics, 2007
- Localisation of renin-angiotensin system (RAS) components in breastBritish Journal of Cancer, 2006